
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc. has demonstrated robust sales growth, with Carvykti averaging a 32% increase in quarterly sales over the past 12 quarters, indicating a strong market demand for its products. Additionally, the rising proportion of community physicians capable of administering CAR T therapies, growing from 29% to 47% within two years, suggests an expanding accessibility and acceptance of these treatments. Positive clinical trial data for anito-cel, along with projections for significant market share and sales growth within the BCMA CAR T market, further underpin a favorable outlook for Arcellx's stock.
Bears say
Arcellx Inc faces a negative outlook primarily due to below-consensus sales estimates for its anito-cel product in the CAR T market, forecasting $11.5 billion in 2035 sales compared to a consensus expectation of $16.5 billion. The company also confronts significant execution risks related to its drug pipeline, coupled with potential political pressures regarding drug pricing and a turbulent biotechnology funding environment. Additionally, despite a substantial patient pool and promising therapy data, barriers affecting patient access to CAR T treatments substantially hinder market adoption, further contributing to financial uncertainties.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares